Phase III Data Shows Biodesix's VeriStrat Proteomic Test Can Predict Response to Tarceva

At the European Lung Cancer Conference last week in Geneva, Biodesix presented data from a multi-center Phase III study that showed VeriStrat was able to identify NSCLC patients most likely to have a "significant survival benefit" from treatment with Tarceva.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.